Compare Citius Pharmaceuticals Inc (CTXR) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Victoria's Secret & Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: Victoria's Secret & Co is far larger — about 507.3× Citius Pharmaceuticals Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Victoria's Secret & Co for 34 Days on average.
| CTXR | VSXY | |
|---|---|---|
Market Cap | $13.62M | $6.91B |
Volume | 132,438 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $99.97 |
52-Week Low | $0.48 | $28.25 |
Typical Hold Time | 17 Days | 34 Days |
Enterprise Value | $3.79M | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with three consecutive earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy driving international growth.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, though rich valuation (P/E 19.33) and rising costs present risks. Key catalysts include sustained margin improvement and global expansion execution, while competition and demand volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
